IO Biotech (IOBT) Competitors $0.48 0.00 (-0.06%) Closing price 04:00 PM EasternExtended Trading$0.51 +0.03 (+6.08%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IOBT vs. AUTL, ETHZ, ATXS, ADCT, PRTC, FDMT, YMAB, EOLS, KMDA, and AURAShould you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Autolus Therapeutics (AUTL), Flag Ship Acquisition (ETHZ), Astria Therapeutics (ATXS), ADC Therapeutics (ADCT), PureTech Health (PRTC), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Evolus (EOLS), Kamada (KMDA), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. IO Biotech vs. Its Competitors Autolus Therapeutics Flag Ship Acquisition Astria Therapeutics ADC Therapeutics PureTech Health 4D Molecular Therapeutics Y-mAbs Therapeutics Evolus Kamada Aura Biosciences IO Biotech (NASDAQ:IOBT) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts recommend IOBT or AUTL? IO Biotech currently has a consensus target price of $8.00, indicating a potential upside of 1,560.78%. Autolus Therapeutics has a consensus target price of $9.12, indicating a potential upside of 484.62%. Given IO Biotech's higher possible upside, equities analysts plainly believe IO Biotech is more favorable than Autolus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IO Biotech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Autolus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is IOBT or AUTL more profitable? Autolus Therapeutics' return on equity of -56.18% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets IO BiotechN/A -281.82% -169.29% Autolus Therapeutics N/A -56.18%-29.61% Which has stronger earnings & valuation, IOBT or AUTL? IO Biotech has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIO BiotechN/AN/A-$95.49M-$1.58-0.30Autolus Therapeutics$10.12M41.03-$220.66M-$0.84-1.86 Do institutionals and insiders believe in IOBT or AUTL? 54.8% of IO Biotech shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 4.8% of IO Biotech shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, IOBT or AUTL? IO Biotech has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Does the media prefer IOBT or AUTL? In the previous week, IO Biotech had 19 more articles in the media than Autolus Therapeutics. MarketBeat recorded 20 mentions for IO Biotech and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 1.02 beat IO Biotech's score of -0.43 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IO Biotech 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAutolus Therapeutics beats IO Biotech on 10 of the 15 factors compared between the two stocks. Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOBT vs. The Competition Export to ExcelMetricIO BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.73M$3.35B$6.10B$10.62BDividend YieldN/A2.28%5.64%4.69%P/E Ratio-0.3022.1685.6627.13Price / SalesN/A265.75527.82206.05Price / CashN/A46.3226.3031.10Price / Book0.689.9612.926.67Net Income-$95.49M-$52.42M$3.30B$276.23M7 Day Performance31.94%5.95%4.80%3.31%1 Month Performance-75.30%11.59%8.11%10.76%1 Year Performance-58.11%25.01%75.85%33.58% IO Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOBTIO Biotech3.4052 of 5 stars$0.48-0.1%$8.00+1,560.8%-58.1%$31.73MN/A-0.3030Gap UpHigh Trading VolumeAUTLAutolus Therapeutics3.8094 of 5 stars$1.59+1.9%$9.12+473.6%-59.5%$415.18M$10.12M-1.89330ETHZFlag Ship AcquisitionN/A$2.48-1.2%N/AN/A$412.72MN/A-0.167ATXSAstria Therapeutics2.6379 of 5 stars$7.36+0.8%$30.20+310.3%-36.6%$411.98MN/A-3.6630ADCTADC Therapeutics2.9451 of 5 stars$4.02+10.0%$7.75+93.0%+24.7%$410.62M$70.84M-2.56310News CoverageAnalyst RevisionPRTCPureTech Health0.071 of 5 stars$18.15+7.4%N/A-6.6%$408.45M$4.83M0.00100Positive NewsGap UpFDMT4D Molecular Therapeutics2.538 of 5 stars$8.35-0.5%$30.40+264.1%-14.2%$391.83M$40K-2.37120YMABY-mAbs Therapeutics1.7695 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150EOLSEvolus4.0103 of 5 stars$6.14+2.5%$21.25+246.1%-60.2%$387.47M$266.27M-6.27170News CoveragePositive NewsKMDAKamada4.5531 of 5 stars$6.87+3.0%$13.00+89.2%+31.2%$383.56M$160.95M20.21360News CoveragePositive NewsAnalyst RevisionAURAAura Biosciences1.9069 of 5 stars$6.17+0.2%$22.00+256.6%-30.6%$382.66MN/A-3.1550Positive News Related Companies and Tools Related Companies Autolus Therapeutics Competitors Flag Ship Acquisition Competitors Astria Therapeutics Competitors ADC Therapeutics Competitors PureTech Health Competitors 4D Molecular Therapeutics Competitors Y-mAbs Therapeutics Competitors Evolus Competitors Kamada Competitors Aura Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOBT) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
